Galapagos receives transparency notification from FMR LLC
2024年8月21日 - 5:01AM
Mechelen, Belgium; 20 August
2024, 22:01 CET; regulated information – Galapagos
NV (Euronext & NASDAQ: GLPG) received a transparency
notification from FMR LLC.
Pursuant to Belgian transparency legislation1,
Galapagos received a transparency notification on 16 August 2024
from FMR LLC, who notified that it holds 3,696,750 of Galapagos’
voting rights, consisting of 3,693,550 ordinary shares and 3,200
equivalent financial instruments. FMR LLC controls investment funds
Fidelity Management & Research Company LLC, FIAM LLC, Fidelity
Management Trust Company, Strategic Advisers LLC, Fidelity
Institutional Asset Management Trust Company, and FMR Investment
Management (UK) Limited, of which Fidelity Management &
Research Company LLC decreased its position to 3,259,440 voting
rights and acquired 3,200 equivalent financial instruments (stock
loan), FIAM LLC increased its position to 122,898 voting rights,
Fidelity Management Trust Company decreased its position to 225,961
voting rights, Strategic Advisers LLC decreased its position to 1
voting right, Fidelity Institutional Asset Management Trust Company
decreased its position to 0 voting rights, and FMR Investment
Management (UK) Limited increased its position to 85,250 voting
rights.
Hence, the first-mentioned controlled
undertaking of the FMR LLC group individually crossed below the 5%
threshold. FMR LLC's holding of 3,696,750 Galapagos' voting rights,
including its controlled undertakings’ holdings, represents 5.61%
of Galapagos' currently outstanding 65,897,071 shares. FMR LLC thus
remains above the 5% threshold of Galapagos’ voting rights. The
full transparency notice is available on the Galapagos website.
About GalapagosWe are a
biotechnology company with operations in Europe and the U.S.
dedicated to developing transformational medicines for more years
of life and quality of life. Focusing on high unmet medical needs,
we synergize compelling science, technology, and collaborative
approaches to create a deep pipeline of best-in-class small
molecules and cell therapies in oncology and immunology. With
capabilities from lab to patient, including a decentralized cell
therapy manufacturing network, we are committed to challenging the
status quo and delivering results for our patients, employees, and
shareholders. For additional information, please
visit www.glpg.com or follow us
on LinkedIn or X.
For further information, please
contact:
Media
inquiries:Marieke Vermeersch +32 479 490
603 media@glpg.com |
Investor
inquiries:Sofie Van Gijsel +1 781 296
1143ir@glpg.com |
Jennifer Wilson + 44
7444 896759media@glpg.com |
Sandra
Cauwenberghs +32 495 58 46 63ir@glpg.com |
1 Belgian Act of 2 May 2007 on the disclosure of
major shareholdings in issuers whose shares are admitted to trading
on a regulated market.
- GLPG Press Release FMR TN_240820_ENG
Galapagos NV (NASDAQ:GLPG)
過去 株価チャート
から 7 2024 まで 8 2024
Galapagos NV (NASDAQ:GLPG)
過去 株価チャート
から 8 2023 まで 8 2024